Literature DB >> 11602752

Induction of cell death in human immunodeficiency virus-infected macrophages and resting memory CD4 T cells by TRAIL/Apo2l.

J J Lum1, A A Pilon, J Sanchez-Dardon, B N Phenix, J E Kim, J Mihowich, K Jamison, N Hawley-Foss, D H Lynch, A D Badley.   

Abstract

Because the persistence of human immunodeficiency virus (HIV) in cellular reservoirs presents an obstacle to viral eradication, we evaluated whether tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo2L) induces apoptosis in such reservoirs. Lymphocytes and monocyte-derived macrophages (MDM) from uninfected donors do not die following treatment with either leucine zipper human TRAIL (LZhuTRAIL) or agonistic anti-TRAIL receptor antibodies. By contrast, such treatment induces apoptosis of in vitro HIV-infected MDM as well as peripheral blood lymphocytes from HIV-infected patients, including CD4(+) CD45RO(+) HLA-DR(-) lymphocytes. In addition, LZhuTRAIL-treated cells produce less viral RNA and p24 antigen than untreated controls. Whereas untreated cultures produce large amounts of HIV RNA and p24 antigen, of seven treated CD4(+) CD45RO(+) HLA-DR(-) cell cultures, viral RNA production was undetectable in all, p24 antigen was undetectable in six, and proviral DNA was undetectable in four. These data demonstrate that TRAIL induces death of cells from HIV-infected patients, including cell types which harbor latent HIV reservoirs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11602752      PMCID: PMC114692          DOI: 10.1128/JVI.75.22.11128-11136.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  52 in total

1.  Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy.

Authors:  D Finzi; J Blankson; J D Siliciano; J B Margolick; K Chadwick; T Pierson; K Smith; J Lisziewicz; F Lori; C Flexner; T C Quinn; R E Chaisson; E Rosenberg; B Walker; S Gange; J Gallant; R F Siliciano
Journal:  Nat Med       Date:  1999-05       Impact factor: 53.440

2.  Functional analysis of TRAIL receptors using monoclonal antibodies.

Authors:  T S Griffith; C T Rauch; P J Smolak; J Y Waugh; N Boiani; D H Lynch; C A Smith; R G Goodwin; M Z Kubin
Journal:  J Immunol       Date:  1999-03-01       Impact factor: 5.422

3.  Protease inhibitor-containing regimens compared with nucleoside analogues alone in the suppression of persistent HIV-1 replication in lymphoid tissue.

Authors:  L Ruiz; J van Lunzen; A Arno; H J Stellbrink; C Schneider; M Rull; E Castellà; I Ojanguren; D D Richman; B Clotet; K Tenner-Racz; P Racz
Journal:  AIDS       Date:  1999-01-14       Impact factor: 4.177

4.  Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

Authors:  H Walczak; R E Miller; K Ariail; B Gliniak; T S Griffith; M Kubin; W Chin; J Jones; A Woodward; T Le; C Smith; P Smolak; R G Goodwin; C T Rauch; J C Schuh; D H Lynch
Journal:  Nat Med       Date:  1999-02       Impact factor: 53.440

5.  TRAIL/Apo-2-ligand-induced apoptosis in human T cells.

Authors:  I Jeremias; I Herr; T Boehler; K M Debatin
Journal:  Eur J Immunol       Date:  1998-01       Impact factor: 5.532

6.  Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma.

Authors:  X D Zhang; A Franco; K Myers; C Gray; T Nguyen; P Hersey
Journal:  Cancer Res       Date:  1999-06-01       Impact factor: 12.701

Review 7.  To die or not to die--the quest of the TRAIL receptors.

Authors:  M Degli-Esposti
Journal:  J Leukoc Biol       Date:  1999-05       Impact factor: 4.962

8.  Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.

Authors:  L Zhang; B Ramratnam; K Tenner-Racz; Y He; M Vesanen; S Lewin; A Talal; P Racz; A S Perelson; B T Korber; M Markowitz; D D Ho
Journal:  N Engl J Med       Date:  1999-05-27       Impact factor: 91.245

Review 9.  TRAIL: a molecule with multiple receptors and control mechanisms.

Authors:  T S Griffith; D H Lynch
Journal:  Curr Opin Immunol       Date:  1998-10       Impact factor: 7.486

10.  Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL.

Authors:  T S Griffith; S R Wiley; M Z Kubin; L M Sedger; C R Maliszewski; N A Fanger
Journal:  J Exp Med       Date:  1999-04-19       Impact factor: 14.307

View more
  45 in total

Review 1.  Hepatocyte death: a clear and present danger.

Authors:  Harmeet Malhi; Maria Eugenia Guicciardi; Gregory J Gores
Journal:  Physiol Rev       Date:  2010-07       Impact factor: 37.312

Review 2.  HIV-1 immunopathogenesis: how good interferon turns bad.

Authors:  Jean-Philippe Herbeuval; Gene M Shearer
Journal:  Clin Immunol       Date:  2006-11-16       Impact factor: 3.969

3.  Independent and cooperative antiviral actions of beta interferon and gamma interferon against herpes simplex virus replication in primary human fibroblasts.

Authors:  Tao Peng; Jia Zhu; Yon Hwangbo; Lawrence Corey; Roger E Bumgarner
Journal:  J Virol       Date:  2007-12-05       Impact factor: 5.103

4.  CD8 T cells utilize TRAIL to control influenza virus infection.

Authors:  Erik L Brincks; Arna Katewa; Tamara A Kucaba; Thomas S Griffith; Kevin L Legge
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

5.  TRAIL limits excessive host immune responses in bacterial meningitis.

Authors:  Olaf Hoffmann; Josef Priller; Timour Prozorovski; Ulf Schulze-Topphoff; Nevena Baeva; Jan D Lunemann; Orhan Aktas; Cordula Mahrhofer; Sarah Stricker; Frauke Zipp; Joerg R Weber
Journal:  J Clin Invest       Date:  2007-07       Impact factor: 14.808

Review 6.  The TRAIL to viral pathogenesis: the good, the bad and the ugly.

Authors:  Nathan Cummins; Andrew Badley
Journal:  Curr Mol Med       Date:  2009-05       Impact factor: 2.222

Review 7.  Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in central nervous system inflammation.

Authors:  Olaf Hoffmann; Frauke Zipp; Joerg R Weber
Journal:  J Mol Med (Berl)       Date:  2009-05-17       Impact factor: 4.599

8.  Expression of the TRAIL receptors in blood mononuclear cells in leukemia.

Authors:  Ugur Deligezer; Nejat Dalay
Journal:  Pathol Oncol Res       Date:  2007-12-25       Impact factor: 3.201

9.  TRAIL death receptor-4, decoy receptor-1 and decoy receptor-2 expression on CD8+ T cells correlate with the disease severity in patients with rheumatoid arthritis.

Authors:  Atil Bisgin; Ender Terzioglu; Cigdem Aydin; Burcak Yoldas; Veli Yazisiz; Nilufer Balci; Huseyin Bagci; Reginald M Gorczynski; Cezmi A Akdis; Salih Sanlioglu
Journal:  BMC Musculoskelet Disord       Date:  2010-08-27       Impact factor: 2.362

10.  HIV induces TRAIL sensitivity in hepatocytes.

Authors:  Challagundla K Babu; Kanitta Suwansrinon; Gary D Bren; Andrew D Badley; Stacey A Rizza
Journal:  PLoS One       Date:  2009-02-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.